GSA Capital Partners’s Denali Therapeutics DNLI Stock Holding History

GSA Capital Partners’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-37,404	Closed	-$772K	–	1584
2023 Q3	$772K	Buy	+37,404	New	+$949K	0.07%	537
2022 Q2	–	Sell	-6,940	Closed	-$223K	–	1480
2022 Q1	$223K	Buy	6,940 +1,106	+19%	+$38.1K	0.03%	1109
2021 Q4	$260K	Sell	5,834 -9,058	-61%	-$429K	0.03%	1036
2021 Q3	$751K	Buy	+14,892	New	+$839K	0.08%	454
2021 Q2	–	Sell	-5,583	Closed	-$319K	–	1368
2021 Q1	$319K	Buy	+5,583	New	+$374K	0.05%	604
2019 Q3	–	Sell	-25,564	Closed	-$531K	–	1463
2019 Q2	$531K	Buy	25,564 +16,244	+174%	+$364K	0.06%	633
2019 Q1	$216K	Buy	+9,320	New	+$195K	0.02%	1202

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSA Capital Partners's DNLI Position: Q4 2023 in Review

GSA Capital Partners sold out of Denali Therapeutics (DNLI) in Q4 2023, closing a stake of 37,404 shares — an estimated $772K sold.

GSA Capital Partners first reported a position in DNLI in Q1 2019 and held it in 7 quarters. The position peaked at $772K in Q3 2023. 209 funds tracked by Wall St. Rank hold DNLI as of Q4 2023.

GSA Capital Partners reported no remaining Denali Therapeutics position as of Q4 2023 after selling out during the quarter.
GSA Capital Partners sold 37,404 Denali Therapeutics shares in Q4 2023, an estimated $772K.
GSA Capital Partners first reported a position in Denali Therapeutics in Q1 2019 and held it in 7 quarters.
GSA Capital Partners's Denali Therapeutics position peaked at $772K in Q3 2023.
209 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2023.

Based on GSA Capital Partners's 13F filing for Q4 2023, filed 16 Feb 2024.